Overweight and obesity Nutritional, Metabolic, Endocrine Overweight and obesity
Conditions
Interventions
Participants are randomised to one of two groups using the website https://www.random.org/lists/.
Active group: Participants receive the dairy product that contains the active ingredi
Sponsors
University of Leeds
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Healthy female participants 2. Aged 18-55 years 3. BMI of 25 – 34.9 kg/m2 4. Not currently dieting to lose or gain weight 5. Not increased physical activity levels in the past 2-4 weeks 6. Regular breakfast eaters 7. Non-smokers 8. =4 liking of study foods (on 9-point Likert scale)
Exclusion criteria
Exclusion criteria: 1. Significant health problems 2. Taking any medication or supplements known to affect appetite or weight within the past month and/or during the study 3. Pregnant, planning to become pregnant or breastfeeding 4. History of anaphylaxis to food 5. Any known food allergies or food intolerance 5. Vegetarians 6. Smokers and those who have recently ceased smoking (within the last 3 months) 7. BMI 34.9 kg/m2 8. Volunteers self-reporting currently dieting or having lost or gained a significant amount of weight in the previous 6 months (>5%) 9. Volunteers who have significantly changed their physical activity patterns in the past 4 weeks (defined as changing them by >150 minutes per week) 10. Participants receiving systemic or local treatment likely to interfere with evaluation of the study parameters 11. Participants (e.g. staff/students) who work in appetite or feeding related areas 12. Non-breakfast eaters
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Body weight is measured using an electronic balance and recorded to the nearest 0.1kg at baseline, every week throughout the intervention and 12 weeks 2. Body composition (fat mass, fat free mass, and percentage body fat) is measured using air displacement plethysomography (BodPod, Concord, CA, USA) at baseline and 12 weeks 2.1. Standing height without shoes is measured to the nearest 0.5cm using a stadiometer at baseline and 12 weeks 2.2. Waist circumference (cm) is measured 1 cm above the top of the participants’ naval after expiration. The measurement is taken 3 times with an average of these measurements being used. Waist circumference is assessed at baseline and 12 weeks 2.3. Hip circumference is measured at the widest part of the participants' hip region. The measurement is taken 3 times with an average of these measurements being used. Hip circumference is assessed at baseline and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Appetite control (satiety, satiation, energy intake, peptide biomarkers and food hedonics) is assessed through recording of food intake and blood testing during two probe days (one to assess the effects of the Active dairy product and one to assess the effects of the Control dairy product) at the start of the intervention and two probe days at the end of the intervention 2. Free-living physical activity levels and sedentary behaviour are assessed using the SenseWear armband mini (SWA; Body Media) for 22 hours per day for 7-8 days at baseline, 1, 10 and 12 weeks | — |
Countries
United Kingdom
Outcome results
None listed